In terms of SEBI Listing Regulations, OneSource Specialty Pharma has informed that a meeting of Board of Directors is scheduled to be held on Friday, January 23, 2026, to consider and approve the unaudited financial results (standalone and consolidated) of the Company for the quarter ended December 31,2025, amongst other matters. Further, as per the provisions of the Company’s Code of Conduct under the SEBI (Prohibition of Insider Trading) Regulations, 2015, the trading window for the Designated Persons of the Company, for the quarter ended December 31, 2025, is closed from January 01, 2026 and shall open after 48 hours after the dissemination of the financial results by the Company.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1788.70 |
| Dr. Reddys Lab | 1276.50 |
| Cipla | 1389.50 |
| Zydus Lifesciences | 1087.35 |
| Lupin | 2284.65 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: